Collectively, this study shows that Trappc9 deficiency causes increased body weight, and this augmented body weight gain leads to disruptions of glucose metabolism and fatty liver, thus establishing the Trappc9 mouse line as a tool for studying obesity and NAFLD, and provides a potential treatment for obesity and NAFLD. This evidence concerns the gene TRAPPC9 and metabolic dysfunction-associated steatotic liver disease.